ESCMID eLibrary
Search results
Icon explanation
Abstract
ePoster
Handout
Image
Journal Article
Presentation
Video
Webcast
-
SY309
Empirical therapy for MDR and XDR Gram-negatives
13 May 2014
Session: Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy?
Relevance:100%
-
SY310
Definitive therapy for ESBL-producers: life beyond carbapenems?
13 May 2014
Session: Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy?
Relevance:100%
-
SY311
Definitive therapy for carbapenemase-producing Enterobacteriaceae: MIC matters?
13 May 2014
Session: Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy?
Relevance:100%
-
SY312
XDR-Pseudomonas aeruginosa and Acinetobacter
13 May 2014
Session: Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy?
Relevance:100%
-
SY192
PK/PDs and susceptibility testing: are we far from the correct direction?
12 May 2014
Session: Colistin: position in the era of multi-resistance
Relevance:100%
-
SY193
The polymyxin resistome
12 May 2014
Session: Colistin: position in the era of multi-resistance
Relevance:100%
-
SY205
Complicated SAB: who we should be worried about and how to evaluate
12 May 2014
Session: Staphylococcus aureus bacteraemia: controversial issues
Relevance:100%
-
SY207
Vancomycin MIC in MSSA and MRSA. What does it mean and does it really matter?
12 May 2014
Session: Staphylococcus aureus bacteraemia: controversial issues
Relevance:100%
-
SY159
Why are some carbapenemases more successful than others?
11 May 2014
Session: Why are some carbapenemases successful?
Relevance:100%
-
SY160
Beta-lactamase and breakpoints: do we have the right ones?
11 May 2014
Session: Why are some carbapenemases successful?
Relevance:100%
Search narrowed by
-
Topics
-
Type of material
-
Time period
